The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis

Background and Purpose: Pervious studies have demonstrated that the loss of EGFR T790M after Osimertinib treatment may be the cause of Osimertinib resistance. Here, we conducted a meta-analysis to evaluate the association between the persistence of EGFR T790M and the clinical benefits of Osimertinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zhe, Li, Lu, Wang, Zhijie, Duan, Jianchun, Bai, Hua, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097959/
https://www.ncbi.nlm.nih.gov/pubmed/32231715
http://dx.doi.org/10.7150/jca.38411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097959/
https://www.ncbi.nlm.nih.gov/pubmed/32231715
http://dx.doi.org/10.7150/jca.38411

Ejemplares similares